NCT05972967 - Safety and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Patients With a Sub-optimal Response to Ravulizumab | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 27, 2023

Primary Completion Date

October 10, 2024

Study Completion Date

October 10, 2024

Conditions

Paroxysmal Nocturnal Hemoglobinuria

Interventions

BIOLOGICAL

OMS906

Biological: OMS906

Trial Locations (5)

Omeros Investigational Site, Aachen

Omeros Investigational Site, Ulm

Omeros Investigational Site, Thessaloniki

Omeros Investigational Site, Lausanne

Omeros Investigational Site, Leeds